1Chemistry,
Washington Univ. in st. louis, st louis, MO, United States; 2Radiology,
Washington Univ. in st. louis, st louis, MO, United States; 3Radiation
Oncology, Washington University in Saint Louis, st louis, MO, United States; 4Radiation
Oncology, Washington Univ. in st. louis, st louis, MO, United States; 5Chemistry,
Washington University in St. Louis, st louis, MO, United States; 6Radiology,
Washington University in Saint Louis, st louis, MO, United States
Bevacizumab, is a powerful anti-angiogenic used in the treatment of tumors. Radiation necrosis, a severe but late occurring injury to normal tissue within and surrounding a radiation treatment field, has been suggested resulting from increases in vascular permeability (leakiness). Bevacizumab may help to repair leaky capillaries and thereby mitigate radiation necrosis. We have recently developed a novel mouse model of radiation necrosis using Gamma Knife irradiation. Here, we use small-animal MRI to monitor the therapeutic effect of bevacizumab and of mouse bevacizumab (B20-4.1.1), which is capable of high-affinity binding to both human and murine VEGF-A.